Autoreactive B Cells in Membranous Nephropathy

Membranous Nephropathy Clinical Trial

— PEPTIDE  

Official title:

PLA2R Autoreactive B-Cell Subsets and Immune Cell Monitoring in Membranous Nephropathy: Identification of Outcome Predictors and Novel Insights Into Disease Pathogenesis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04095156
• Other study ID #: PEPTIDE
• Status: Recruiting
• Start date: September 12, 2019
• Est. completion date: December 2023

Study information

• Verified date: November 2022
• Source: Mario Negri Institute for Pharmacological Research
• Contact: Manuel Podestà, MD
• Phone: 003903545351
• Email: manuel.podesta[@]guest.marionegri.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome (NS) in adults. The majority of MN patients show detectable circulating antibodies against the M-type phospholipase A2 receptor (PLA2R). Infusion of anti-CD20 monoclonal antibodies results in a profound depletion of B-cells, which are thought to be responsible for anti-PLA2R production. B-cell depletion is followed by NS remission in 70% of cases. Limited evidence highlighted that differences in the B- and T-cell compartments may exist between responders and non-responders. Owing to the non-homogenous efficacy of anti-CD20 treatment, investigators hypothesize that in MN patients who experience NS remission after B-cell depleting therapy, autoreactive B-cells may be mostly circulating, whereas in patients who do not respond to the same treatment, autoreactive B-cells may chiefly reside into secondary lymphoid organs - and thus be more resistant to the drug action. Researchers will therefore extensively analyze the circulating immune repertoire of MN patients before and after the infusion of B-cell lineage depleting agents, assessing the presence of circulating PLA2R autoreactive B cells from appropriately stratified responder and non-responder patients. Patients and healthy controls will be enrolled in this study. Patients will be stratified according to gender, anti-PLA2R status, type of B-cell lineage depleting agent received and response to treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 86
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients inclusion criteria

• Males and females.

• Adults (> 18 years old).

• Patients with biopsy-proven idiopathic MN, who are candidate to receive (prospective cohort) or who already received (retrospective cohort) a B-cell depleting treatment as per center clinical practice.

• Mental state is such that they are able to understand and give valid consent to the study;

• Written informed consent according to the guidelines of the Declaration of Helsinki.

Healthy volunteers inclusion criteria

• Male and female (>18 years) not known to suffer of any significant illness;

• Not assuming any medication or drug on a regular basis;

• Negative urine analysis (urine dipstick, multistick);

• Written informed consent according to the guidelines of the Declaration of Helsinki

Exclusion Criteria:

Patients exclusion criteria

• Reasonable possibility of a secondary cause of MN (e.g.systemic lupus erythematosus, active hepatitis B, malignancy, drugs such as gold salts and penicillamine).

• Legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent.

Healthy volunteers exclusion criteria

• Legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent.

Related Conditions & MeSH terms

• Glomerulonephritis, Membranous
• Kidney Diseases
• Membranous Nephropathy

Intervention

Diagnostic Test:
• In vitro assays.
Biochemical and flow-cytometry analysis of specimen collected.

Locations

Country	Name	City	State
Italy	Centro di Ricerche Cliniche per le Malattie Rare " Aldo e Cele Daccò"	Ranica	BG

Sponsors (1)

Lead Sponsor	Collaborator
Mario Negri Institute for Pharmacological Research

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differences between anti-PLA2R positive MN patients and anti-PLA2R negative MN patients and healthy controls in the frequency of anti-PLA2R autoreactive circulating B-cells.		Changes from baseline and 3,6,9,12 and 24 month.
Primary	Differences between anti-PLA2R positive MN patients and anti-PLA2R negative MN patients and healthy controls in the frequency of immunoglobulin- and cytokine-secreting circulating B-cell subsets in resting and stimulated conditions.		Changes from baseline and 3,6,9,12 and 24 month.
Primary	Differences between anti-PLA2R positive MN patients and anti-PLA2R negative MN patients and healthy controls in spontaneous / stimulated immunoglobulin (including anti-PLA2R) and cytokine release from circulating B-cell subpopulations.		Changes from baseline and 3,6,9,12 and 24 month.
Primary	Differences between MN patients and healthy controls, and between responders and non-responders in the frequency of circulating B-cell subpopulations.		Changes from baseline and 3,6,9,12 and 24 month.
Primary	Differences between MN patients and healthy controls, and between responders and non-responders in the frequency of circulating T-cell, NK-cell, monocyte and dendritic cell subpopulations.		Changes from baseline and 3,6,9,12 and 24 month.